Reference
Liu M, et al. Ibrutinib improves the efficacy of anti-CD19-CAR T-cell therapy in patients with refractory non-Hodgkin lymphoma. Cancer Science 112: 2642-2651, No. 7, Jul 2021. Available from: URL: http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1349-7006
Rights and permissions
About this article
Cite this article
Anti-cd19-car-transduced-t-cells/ibrutinib. Reactions Weekly 1889, 32 (2022). https://doi.org/10.1007/s40278-022-08711-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-022-08711-4